Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
Baylor College of Medicine
St. Jude Children's Research Hospital
Valent Technologies, LLC
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Bayer
Masonic Cancer Center, University of Minnesota
New York Medical College
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)
Vanderbilt University
National Cancer Institute (NCI)
Ann & Robert H Lurie Children's Hospital of Chicago